Partner Headlines - BMRN

  1. Benzinga's M&A Chatter for Monday November 24, 2014

    Benzinga
  2. BioMarin buying Prosensa

    IBD
  3. Trio Of Major Deals Disclosed

    IBD
  4. Mid-Afternoon Market Update: Trina Solar Drops After Quarterly ...

    Benzinga
  5. Mid-Day Market Update: Dow Edges Lower; Platinum Underwriters ...

    Benzinga
  6. Mid-Morning Market Update: Markets Open Higher; BioMarin To Acquire ...

    Benzinga
  7. Benzinga's Volume Movers

    Benzinga
  8. BioMarin Buying Prosensa, Backing Up Troubled Drug

    IBD
  9. Stocks Hitting 52-Week Highs

    Benzinga
  10. Morning Market Movers

    Benzinga
  11. Stock Futures Trending Higher; Kate Spade Bags An Upgrade

    IBD
  12. BioMarin Pharmaceuticals To Acquire Prosensa

    Benzinga
  13. Benzinga's Top #PreMarket Gainers

    Benzinga
  14. US Stock Futures Up Ahead Of Economic Data

    Benzinga
  15. Stocks Hitting 52-Week Highs

    Benzinga
  16. Benzinga's Top Upgrades

    Benzinga
  17. Benzinga's M&A Chatter for Tuesday October 21, 2014

    Benzinga
  18. BioMarin Weathers The Storm

    Benzinga
  19. 4 Top-Rated Drugmakers Beat Q2 Earnings Estimates

    IBD
  20. Biogen Hemophilia Drugs Launch Into The Unknown

    IBD
  21. UPDATE: Credit Suisse Upgrades BioMarin Pharmaceutical

    Benzinga
  22. Benzinga's Top Upgrades

    Benzinga
  23. BioMarin, Medivation Buck Biotech Short Interest Trend (BIIB, ...

    Benzinga
  24. Amgen, BioMarin Lead Biotech Short Interest Trend (AMGN, BIIB, ...

    Benzinga
  25. Top Trending Tickers On StockTwits For February 18

    Benzinga
  26. BioMarin Bucks Biotech Short Interest Trend (BIIB, BMRN, MDVN)

    Benzinga
  27. You Can No Longer Ignore Biotech

    GuruFocus
  28. New Year Short Interest Swings In Biotech (BIIB, BMRN, MDVN)

    Benzinga
  29. Celgene, Dendreon Lead Short Interest Trend In Biotechs (BMRN, ...

    Benzinga
  30. UPDATE: Piper Jaffray Initiates Coverage on BioMarin Pharmaceutical ...

    Benzinga
  31. UPDATE: Piper Jaffray Initiates On BioMarin Pharmaceuticals On ...

    Benzinga
  32. BioMarin Wins FDA Panel Vote, Cuts Deal With Myriad

    IBD
  33. Benzinga's Top #PreMarket Gainers

    Benzinga
  34. BioMarin Confirms FDA Panel Recommends Approval of Vimizim for ...

    Benzinga
  35. BioMarin Stock Trading Halted Today for FDA Endocrinologic and ...

    Benzinga
  36. Gilead Sciences Leads In Rising Short Interest Among Biotechs ...

    Benzinga
  37. Catalyst Stock Plunge: Ugly In Orphan Drug Land

    YCharts
  38. BioMarin Initiates Phase 3 BMN 673 Trial for Metastatic gBRCA ...

    Benzinga
  39. Short Sellers Retreat From Biogen Idec, Move On Pharmacyclics ...

    Benzinga
  40. US Oncology, Biomarin Announce Collaboration to Launch PARP Inhibitor ...

    Benzinga
  41. Roche

    IBD
  42. BioMarin Announces 5 Poster Presentations on BMN 673 at AACR-NCI-EORTC ...

    Benzinga
  43. Short Sellers Move On Amgen, Vertex (AMGN, PCYC, VRTX)

    Benzinga
  44. Orphan Drugs: No (Payer) News Is Good News

    YCharts
  45. BioMarin Presents Positive Phase 1/2 Data on BMN 673 in Breast ...

    Benzinga
  46. BioMarin, Celgene Lead Trend in Biotech Short Interest (BRMN, ...

    Benzinga
  47. Market Primer: Friday, September 20: US Markets Fall As Investors ...

    Benzinga
  48. Benzinga's M&A Chatter for Thursday September 19, 2013

    Benzinga
  49. Report: Roche Lines up $15B in Debt to Buy BioMarin

    FoxBusiness
  50. Benzinga's Volume Movers

    Benzinga
  51. Benzinga's Top Pre-Market Gainers

    Benzinga
  52. UPDATE: Stifel Downgrades BioMarin Pharmaceutical on Appropriate ...

    Benzinga
  53. Benzinga's Top Pre-Market Gainers

    Benzinga
  54. Alexion, Pharmacyclics Buck Trend in Biotech Short Interest (ALXN, ...

    Benzinga
  55. Biomarin Pharmaceutical, Inc. (BMRN) CEO Jean Jacques Bienaime ...

    GuruFocus
  56. Biomarin Pharmaceutical, Inc. (BMRN) CEO Jean Jacques Bienaime ...

    GuruFocus
  57. Biomarin Pharmaceutical, Inc. (BMRN) CEO Jean Jacques Bienaime ...

    GuruFocus
  58. UPDATE: Stifel Nicolaus Upgrades BioMarin Pharmaceutical on Catalysts

    Benzinga
  59. Biomarin Pharmaceutical, Inc. (BMRN) CEO Jean Jacques Bienaime ...

    GuruFocus
  60. Biomarin Pharmaceutical, Inc. (BMRN) CEO Jean Jacques Bienaime ...

    GuruFocus
  61. J.P. Morgan Reiterates Overweight Rating, $60 PT on BioMarin ...

    Benzinga
  62. Biomarin Pharmaceutical, Inc. (BMRN) CEO Jean Jacques Bienaime ...

    GuruFocus
  63. Biomarin Pharmaceutical, Inc. (BMRN) CEO Jean Jacques Bienaime ...

    GuruFocus
  64. BioMarin Pharmaceutical Inc. (BMRN) CEO Jean Jacques Bienaime ...

    GuruFocus
  65. Biomarin Pharmaceutical, Inc. (BMRN) CEO Jean Jacques Bienaime ...

    GuruFocus
  66. Biomarin Pharmaceutical, Inc. (BMRN) CEO Jean Jacques Bienaime ...

    GuruFocus
  67. UPDATE: Wedbush Reiterates BioMarin Pharmaceuticals at Neutral ...

    Benzinga
  68. Biomarin Pharmaceutical, Inc. (BMRN) CEO Jean Jacques Bienaime ...

    GuruFocus
  69. BioMarin, Prestige Brands and Other Top Performing Health Care ...

    Benzinga
  70. Biomarin Pharmaceutical, Inc. (BMRN) CEO Jean Jacques Bienaime ...

    GuruFocus
  71. Weekly Top Insider Sells? AAPL, GILD, BMRN, and PCLN

    GuruFocus
  72. Biomarin Pharmaceutical, Inc. (BMRN) CEO Jean Jacques Bienaime ...

    GuruFocus
  73. BioMarin Pharmaceutical Inc. (BMRN) CEO Jean Jacques Bienaime ...

    GuruFocus
  74. Biomarin Pharmaceutical, Inc. (BMRN) CEO Jean Jacques Bienaime ...

    GuruFocus
  75. Myriad Genetics Stock Hits High On Earnings Beat

    IBD
  76. Highs & Lows: BioMarin Pharmaceutical, Best Buy, and Skullcandy

    SchaeffersResearch
  77. BioMarin soars on drug data

    IBD
  78. Mid-Afternoon Market Update: Markets Rally, Vringo Jumps

    Benzinga
  79. UPDATE: Canaccord Genuity Raises PT to $56 on BioMarin Pharmaceutical ...

    Benzinga
  80. Mid Morning Market Update: Markets Decline, Stifel Financial ...

    Benzinga
  81. Stocks Hitting 52-Week Highs

    Benzinga
  82. BioMarin Stock Soars On Positive Drug Data

    IBD
  83. BioMarin Phase 3 Study of GALNS Meets Primary Endpoint

    Benzinga
  84. Biomarin Pharmaceutical, Inc. (BMRN) CEO Jean Jacques Bienaime ...

    GuruFocus
  85. BioMarin Pharmaceutical Inc. Reports Operating Results (10-Q)

    GuruFocus
  86. BioMarin Pharmaceutical Inc. (BMRN) CEO Jean Jacques Bienaime ...

    GuruFocus
  87. UPDATE: Jefferies Raises PT to $46 on BioMarin Pharmaceutical ...

    Benzinga
  88. BioMarin Pharmaceutical Inc. (BMRN) CEO Jean Jacques Bienaime ...

    GuruFocus
  89. BioMarin Pharmaceutical Inc. (BMRN) CEO Jean Jacques Bienaime ...

    GuruFocus
  90. BioMarin Pharmaceutical Inc. (BMRN) CEO Jean Jacques Bienaime ...

    GuruFocus
  91. Health Care Sector Wrap

    FoxBusiness
  92. Benzinga's Top Downgrades

    Benzinga
  93. Biotechs In Motion As New Drug Pipeline Brims

    IBD
  94. BioMarin Pharmaceutical Reports Inducement Grants Under NASDAQ ...

    Benzinga
  95. Dendreon, Pharmacyclics and Other Biotech Takeover Targets

    Benzinga
  96. BioMarin Pharmaceutical, Health Net Among Stocks Up on High Volume ...

    FoxBusiness
  97. Merck &, Questcor Pharmaceuticals, Other Stocks Hit 52-Week Highs ...

    FoxBusiness
  98. Amylin Pharmaceuticals, Constellation Brands Among Stocks Setting ...

    FoxBusiness
  99. Analyst Initiations: BMRN, FB, and MDVN

    SchaeffersResearch
  100. Benzinga's Top Pre-Market Gainers

    Benzinga
Trading Center